The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Vincent A. Miller

Thoracic Oncology Service

Division of Solid Tumor Oncology

Department of Medicine

Memorial Sloan-Kettering Cancer Center

USA

[email]@mskcc.org

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, USA. 2000 - 2008
  • Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. 2003 - 2008
  • Department of Medicine, Memorial Sloan-Kettering Cancer Center and Cornell University Medical College, New York, NY 10021, USA. 1997 - 2006

References

  1. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. Miller, V.A., Riely, G.J., Zakowski, M.F., Li, A.R., Patel, J.D., Heelan, R.T., Kris, M.G., Sandler, A.B., Carbone, D.P., Tsao, A., Herbst, R.S., Heller, G., Ladanyi, M., Pao, W., Johnson, D.H. J. Clin. Oncol. (2008) [Pubmed]
  2. EGFR mutations and EGFR tyrosine kinase inhibition in non-small cell lung cancer. Miller, V.A. Semin. Oncol. Nurs (2008) [Pubmed]
  3. Optimizing therapy in previously treated non-small cell lung cancer. Miller, V.A. Semin. Oncol. (2006) [Pubmed]
  4. Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities. Miller, V.A., Hirsch, F.R., Johnson, D.H. J. Clin. Oncol. (2005) [Pubmed]
  5. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. Miller, V.A., Kris, M.G., Shah, N., Patel, J., Azzoli, C., Gomez, J., Krug, L.M., Pao, W., Rizvi, N., Pizzo, B., Tyson, L., Venkatraman, E., Ben-Porat, L., Memoli, N., Zakowski, M., Rusch, V., Heelan, R.T. J. Clin. Oncol. (2004) [Pubmed]
  6. Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer. Miller, V.A., Johnson, D.H., Krug, L.M., Pizzo, B., Tyson, L., Perez, W., Krozely, P., Sandler, A., Carbone, D., Heelan, R.T., Kris, M.G., Smith, R., Ochs, J. J. Clin. Oncol. (2003) [Pubmed]
  7. Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer. Miller, V.A., Krug, L.M., Ng, K.K., Pizzo, B., Perez, W., Heelan, R.T., Kris, M.G. J. Clin. Oncol. (2000) [Pubmed]
  8. Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. Miller, V.A., Benedetti, F.M., Rigas, J.R., Verret, A.L., Pfister, D.G., Straus, D., Kris, M.G., Crisp, M., Heyman, R., Loewen, G.R., Truglia, J.A., Warrell, R.P. J. Clin. Oncol. (1997) [Pubmed]
  9. Phase II trial of chloroquinoxaline sulfonamide (CQS) in patients with stage III and IV non-small-cell lung cancer. Miller, V.A., Rigas, J.R., Tong, W.P., Reid, J.R., Pisters, K.M., Grant, S.C., Heelan, R.T., Kris, M.G. Cancer Chemother. Pharmacol. (1997) [Pubmed]
  10. Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer. Miller, V.A., Ng, K.K., Grant, S.C., Kindler, H., Pizzo, B., Heelan, R.T., von Roemeling, R., Kris, M.G. Ann. Oncol. (1997) [Pubmed]
 
WikiGenes - Universities